CUF & NANO4, NANOTECHNOLOGY IN DIAGNOSIS

CUF started a molecular diagnostic validation study for Chronic Myeloid Leukemia, in partnership with the startup Nano4 Global. The goal is to obtain a faster and more accessible diagnosis of this rare disease, bringing positive impacts on the monitoring of patients.

NANO4 CML (Chronic myeloid leukemia) will be one of the first nanotechnology-based diagnostic systems to be launched in Europe. CUF, through CUF Oncology and its network of oncological care, joined this trial and clinical validation not only to support a more efficient and quick medical decision process, and to improve the quality of life of patients, but also to support innovative techonologies and companies.